doi:10.3109/15563659309000395
Both tirzepatide and semaglutide are designed for chronic, ongoing use rather than short-term weight loss cycles
A new report by financial research companies Morningstar and PitchBook projected that the GLP-1 market will hit $200 billion by 2031 and that 16 new obesity drugs could emerge within the next five years
However, in the matched cohort, a full 13,767 individuals had more than two years of follow-up time, with nearly half of those (n = 6,650) having more than four years
always consult your healthcare provider
What most of us didnt understand in the 1980s and 90s is what were finally accepting today: Contrary to traditional belief, having a fuller body type is often not due to laziness or a lack of discipline